

REMARKS

With entry of this Amendment, claims 1-6, 8-13, 16-25, and 28-32 have been canceled herein without prejudice to pursuing their subject matter at a future time. Furthermore, no estoppels are intended by their cancellation. Applicants reserve the right to prosecute the originally filed claims in the future.

Claims 33, 34, and 35 have been added. Since all of these inventions are reasonably conveyed by the specification and original claims, there is no issue of new matter. Claims 7, 14-15, 26-27, and 33-35 are pending in this application.


Applicants thank the Office for the indication that Claim 7 would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claim. Applicants are also grateful for the indication that a genus of chemical entities based on the elected compound, N3-(2-methoxybenzyl)-5-(4-phenoxyphenyl)-pyrazine-2,3-diamine and pharmaceutical compositions comprising such chemical entities would also be allowable. Applicants have amended the claims accordingly. As the pending rejections have been rendered moot, Applicants request that they be withdrawn.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 14, 2005

By: 
Lauren L. Stevens
Reg. No. 36,691
Customer No. 22,852